Chief Executive Officer
Chief Scientific Officer
Boris Tabakoff, PhD
Boris Tabakoff was trained as a molecular pharmacologist; he also received training in behavioral genetics. He received his PhD from the University of Colorado in 1970. Dr. Tabakoff’s research endeavors have received significant peer recognition and he has been the recipient of The William Peck Scientific Research Award, The Research Society on Alcoholism Scientific Excellence Award, The Jellinek Memorial Award for Major Contributions to Alcoholism Research, and The Florence Rena Sabin Award for Exceptional Contributions to the University of Colorado Health Sciences Center, among others.
Dr. Tabakoff has provided leadership within the alcohol research community by his active role as President of the Research Society on Alcoholism and President of the International Society for Biomedical Research on Alcoholism. Additionally, Dr. Tabakoff has an appointment as a member of the World Health Organization (W.H.O.) Expert Advisory Panel on Drug Dependence and Alcohol Problems, and as Scientific Director of the W.H.O. sponsored Multi-Center Study on State and Trait Markers in Alcoholism. Additionally, Dr. Tabakoff has helped to lead Federal Government alcoholism research efforts through his past position as Scientific Director for NIAAA’s Intramural Research Programs and in his past role as Acting Deputy Director for NIAAA.
In his role as Chairman of the Department of Pharmacology, and through his own current research endeavors, Dr. Tabakoff has encouraged the application of the most modern technology to studies of alcoholism and other drug abuse. An example of this can be seen in the structure of the Integrative Neuroscience Initiative on Alcoholism (INIA) which is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA). Dr. Tabakoff is part of the organizing committee and scientific advisory committee for INIA, and he has championed the utilization of several technology platforms as means of solving the complex problems of alcohol dependence and craving. Dr. Tabakoff is also the founder and President of Lohocla Research Corporation, which has played an important role in introducing target structure based drug design into the alcoholism pipeline development area and has produced genetically-based diagnostic tools in the areas of alcoholism and depression. Through his research career, Dr. Tabakoff has published well over 300 research reports, reviews, and commentaries in the areas of alcohol addiction, other drug addictions, and mental health.
Executive Director of Laboratory Science
Paula Hoffman, PhD
Dr. Hoffman received a B.A. from the University of Chicago, M.S. from Yale University and Ph.D. from Mt. Sinai Graduate School. Her research interests include the molecular mechanisms of alcohol and drug tolerance and dependence, focusing on the role of neuropeptides, neurotrophins and the brain glutamate neurotransmission systems. She is also using microarray (genomic) and proteomic technologies to investigate the genetic basis of alcohol-related behaviors. Dr. Hoffman has authored more than 200 scientific papers. Dr. Hoffman is active in several scientific societies. She served on the Subcommittee on Women in Pharmacology of the American Society for Pharmacology and Experimental Therapeutics. She has served on the Board of Directors for the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism (ISBRA) and is also the ISBRA Treasurer and supervisor for the Society office. She chaired the Board of Scientific Counselors for the National Institute on Alcohol Abuse and Alcoholism and has served on Scientific Advisory Boards for several national Alcohol Research Centers.
Chief Operations Officer
Chief Financial Officer
Jim Finster, MPA
In 2019, Jim Finster joined Lohocla Research Corporation (Lohocla) in the role of chief operations officer. In his prior position, Jim pursued a practice in public administration at the University of Colorado for sixteen years. Currently, Jim provides leadership and administrative and technological expertise directed toward advancing the mission and goals of Lohocla. He is proficient in the appropriate application of information technology to facilitate, monitor, and analyze performance and develops customized software as a “full-stack” builder and server manager. His IT skills range from the assembly, upgrading, and trouble-shooting of hardware through the creation and management of server and end-user software. He also has extensive experience with creating frameworks for collecting and managing data in many formats. In addition, Jim has a long track record of organizing effective, committed, and productive teams. He has broad experience with the management and development of personnel through fostering loyalty and building community as well as substantial experience with project management and business plan development and implementation. Jim received an A.B. from Hamilton College with concentrations in English literature and religion and a M.P.A. from the CU Denver School of Public Affairs.
Research Advisory Board
Professor, Shipley University Chair in Comparative Oncology
Colorado State University
Daniel Gustafson, PhD
Dr. Gustafson is a professor of cancer pharmacology and director of the pharmacology core. He also holds the Shipley University Chair in Comparative Oncology. The Gustafson laboratory focuses on developing therapeutic treatment modalities for cancer with an emphasis on the pharmacology of agents and development of animal, pharmacokinetic, and mathematical model systems that better reflect the clinical progression and pathology of cancer. Current projects include mechanism of action and pharmacology of the MEK inhibitor AZD6244 in human melanoma cell lines and tumor xenografts in mouse models alone and in combination with cytotoxic chemotherapy; drug combinations that target stromal and cancer cells; and pharmacokinetic modeling to describe, simulate and predict effects.
Walker Downey & Associates, Inc.
Daniel McLain, PhD
Daniel E. McLain, PhD is President of Walker Downey & Associates, Inc., a medical product safety and development consulting firm and certified Veteran-Owned Small Business (cVOSB) located in the heart of the Third Coast Scientific/Biotechnology Community (Madison, WI). He received his MS/PhD in nutritional toxicology and preventive medicine from Cornell University and has more than 30 years of broad-based experience in toxicology, drug and device development, vaccine development, statistics, and risk assessment. He has specific expertise in medical device material biocompatibility, immunotoxicology, and is the current AAMI US Chair for TC194/WG7 and convener of ISO 10993 – Biological Evaluation of Medical Devices – Part 11: Systemic Toxicity Evaluation (standard revised 2006; reaffirmed 2010). He has contributed to and has meaningful personal experience with IND, BLA, 510(k), GTAC, CTD and MEDDEV 2.7.1 CER preparation. He is fully experienced with the design, conduct, analysis, and reporting of preclinical safety and pharmacokinetic studies for drugs, devices, biologics, and combination products, and with the international regulatory submissions associated with them.
Tech Reg Services Inc. (TRSI)
Steven Pikulin, PhD
Steven is currently the president of TechReg Services, Inc. (TRSI). He has personally written well over 100 domestic/international new drug, biologic, and generic CMC submissions for numerous healthcare companies across a wide variety of dosage forms including orally administered immediate and extended release solids, semi-solids and liquids; parenterals; nasal sprays, metered dose, and dry powder inhalation products; peptides; oligonucleotides; liquid inhalation anesthetics; pulmonary surfactants; dermal and transdermal products; medical devices; and a number of other drug therapies. His role in these projects usually involved complete management of CMC development as well as preparation of the corresponding regulatory documentation, cGMP compliance audits and interaction with the regulatory agencies. Prior to founding TRSI in 1999, he held various positions in over 20 years in the pharmaceutical industry in Drug Discovery, Manufacturing Operations, Analytical Research, Quality Control, Quality Assurance, and CMC Regulatory Affairs. He has also taught with various government, trade, and academic organizations, and has presented to the FDA and non-US regulatory agencies on CMC related topics. He has been a visiting scientist at Rutgers University, where he performs select non-GMP API and impurity syntheses under contract, and from 1998 to 2012 was an adjunct professor in the graduate Pharmaceutics/Regulatory Affairs programs at Long Island University, where he taught several courses related to pharmaceutics and regulatory affairs.
Fast-Track Drugs and Biologics, LLC
Janet Ransom, PhD
President and Co-founder of Fast-Track Drugs and Biologics, Dr. Ransom has over 25 years experience in biomedical research including product inception, research, development, clinical trials, and product licensure. She has managed diverse projects including the development of therapeutic cancer vaccines, therapeutic biological products and drugs to treat carcinomas, genetically engineered T cells for the treatment of AIDS/HIV, antitoxins for the treatment of neurotoxins, biological defense vaccines, pipeline for the treatment of substance abuse, and cardiovascular disease in vitro diagnostic tests. Depending upon the development phase of these projects, she was involved with the regulatory development strategy, clinical trial design, pre-clinical development plans, and data analysis and reporting to support product licensure. Dr. Ransom has designed and written Phase 1, 2, 3, and 4 clinical protocols to assess the safety and therapeutic effect of numerous biological and chemical agents for the treatment of malignancies. Furthermore, she has analyzed data from multi-institutional clinical trials and written the Clinical Summary Reports of numerous phase 2 and 3 studies according to the ICH Guidelines for inclusion in Biologics License Applications and New Drug Applications. Her clinical trials coordination activities have included the development of a clinical data management system using an Oracle database, electronic data capturing technology, and web-based applications to collect, store, analyze and report pre-clinical and clinical data in support of therapeutic product development for government and pharmaceutical clients. She established systems specifications and implemented system installation, validation, release for production, and system oversight for multiple large multicenter clinical trials enrolling thousands of study participants.
Director of Clinical Research Services
Clinical and Translational Research Institute at UCSD
Mark Wallace, MD
Mark Wallace, MD, is a board-certified anesthesiologist who specializes in multi-modal pain management. As a pain management specialist, he evaluates, diagnoses and treats all forms of pain, though most of his patients are affected by chronic pain. Since 1996, Dr. Wallace has been program director of UC San Diego Health’s Center for Pain Medicine, which is dedicated to reducing and eliminating suffering, and improving function in individuals with lower-back or other spine-related pain issues, joint and muscular-skeletal pain or pain due to surgery, injury, nerve damage, psychological factors and metabolic problems such as diabetes. Under his leadership, the Center for Pain Medicine was named a Clinical Center of Excellence in Pain Management in 2010 and 2014 by the American Pain Society. The award recognizes pain care teams that “provide outstanding exemplary care.” Dr. Wallace is also chair of the Division of Pain Medicine within UC San Diego School of Medicine’s Department of Anesthesiology and has co-authored 119 peer-reviewed articles and five books on pain medicine. He is active in clinical trials of investigational drug and techniques for managing chronic pain.
Prior to joining UC San Diego Health, he was an assistant clinical professor in the Department of Anesthesiology at University of Texas, Houston. Dr. Wallace completed sub-speciality fellowship training in pain management at UC San Diego School of Medicine and residency training in anesthesiology at University of Maryland School of Medicine in Baltimore. He interned in general surgery at Washington Hospital Center in Washington, D.C. and earned his medical degree at Creighton University School of Medicine in Omaha. Dr. Wallace is board-certified in anesthesiology and pain medicine.
He received the Leonard Tow Humanism in Medicine Award in 2012 and is consistently elected as one of San Diego’s Top Doctors in San Diego Magazine’s “Physicians of Exceptional Excellence” annual survey. Dr. Wallace is currently a member of the Board of Directors of the American Pain Society and serves on scientific planning meetings for both national and international meetings, including the World Congress of Pain, World Institute of Pain, American Academy of Pain Medicine and American Society of Regional Anesthesia and Pain Medicine.